Most recently, Trizzino worked for Novavax as the senior vice president.
Prior to joining Novavax, he held senior executive positions at MedImmune acquired by AstraZeneca, and ID BioMedical, now part of GlaxoSmithKline.
Immunovaccine chairman Albert Scardino said as their development program accelerates with a second cancer vaccine in the clinic, they are pleased to be joined by someone with John’s experience in partnering, licensing and distribution.